Kuros receives European Patent for fibrin-based biomaterial-biologic combination products
Allowance of this patent application enhances protection of Kuros’ fibrin-based technologies and of many of its fibrin-based programs including its leading clinical stage programs, such as KUR-111 for tibial plateau fractures, KUR-113 for tibial shaft fractures, and KUR-212 for mesh grafting in burns patients. All of these programs are currently in Phase II clinical testing.
Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The company’s product candidates are based on one of two different matrix technology platforms; fibrin or synthetic biomaterial matrices. Allowance of this patent application strengthens Kuros’ position in the development of therapeutic products based on the addition of drugs into fibrin matrices.
EP 1124590 is the European counterpart of already granted US patents US 6,331,422 & US 6,607,740.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.